For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Current evidence of metastatic disease documented by either bone lesions on
             radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic
             resonance imaging (CT/MRI).

          -  Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone
             (GnRH) analogue or a surgical/medical castration with testosterone level of
             ≤1.73nmol/L (50ng/dL)

        For crossover phase for participants originally randomized to Arm D3 or Arm D4 only:

          -  Previously randomized to Arm D3 or D4; had histologic confirmation of adenocarcinoma
             of the prostate and evidence of Stage IV disease (as defined by American Joint
             Committee of Cancer criteria (AJCC criteria) prior to randomization

        Exclusion Criteria:

          -  Presence of visceral metastases in the liver

          -  Active brain metastases or leptomeningeal metastases

          -  Active, known, or suspected autoimmune disease or infection

          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or
             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint
             pathways

        For crossover phase for participants originally randomized to Arm D3 or Arm D4 only:

          -  Prior radiation therapy within 14 days prior to first dose of nivolumab combined with
             ipilimumab

          -  Have received systemic anti-cancer therapy after the last dose of study treatment
             (ipilimumab or cabazitaxel)

        Other protocol-defined inclusion/exclusion criteria apply